Treatment guidelines play an important role in managing patients with chronic diseases, including hemophilia. Treatment guidelines offer guidance on treatment selection and patient choices, taking into account outcomes, and balance both efficacy and…
MASAC Document 283 - Physical Therapy Management for People with Bleeding Disorders and Chronic Pain
Authors:Nancy Durben, PT, MSPT, PCS (1), J. Nicole Clark, PT, DPT (2), Jennifer R Newman, PT, MSPT (3), Lora Joyner, PT, MS (4), Ryan J. Rushton, PT, DPT, MHA, CLT (5), Lena M. Volland, PT, PhD(c) (6), Tyler Buckner, MD (2…
The landscape for hemophilia treatment options has greatly evolved in the last few years. Most recently is the addition of gene therapy for the treatment of bleeding disorders. {Gene therapy adds a new gene or replaces or repairs a mutated gene in a…
New documents issued by NBDF’s Medical and Scientific Advisory Council (MASAC) cover a wide range of topics relevant to bleeding disorder patients in the U.S. and abroad. They encompass recommendations for treatment with licensed therapies, chronic…
Teri joined the National Bleeding Disorders Foundation in 2022 to spearhead the launch and management of the National Bleeding Disorders Venture Fund, LLC, Pathway to Cures. Focused on equity investments in companies developing therapies for…
Anna Cheshire is the program manager at the Colorado Chapter of NBDF. Prior to joining the chapter, she worked in program roles at several museums and nonprofit organizations, where she discovered her passion for working directly with people to…
The U.S. Food and Drug Administration (FDA) has approved BEQVEZ™ (Pfizer, Inc.), a new hemophilia B gene therapy product. It is designed with bioengineered adeno-associated virus (AAVs) vectors to introduce a working copy of the factor IX…
Government Relations Update – April 2024 Federal Affordable Care Act: The Department of Health and Human Services on April 26 released the final rule on Section 1557 of the ACA that…